Micros Systems (NASDAQ: MCRS), FleetCor Technologies, Inc. (NYSE: FLT), Gilead Sciences, Inc. (NASDAQ: GILD), Hanger Orthopedic (NYSE: HGR), KB Home (NYSE: KBH), Lennar Co. (NYSE: LEN) and Dresser-Rand (NYSE: DRC) had ratings and price targets on them adjusted by analysts.
FleetCor Technologies, Inc. (FLT) had its price target raised by Citigroup (NYSE:C) to $36.00.
Gilead Sciences, Inc. (GILD) had its price target raised by ThinkEquity from $50.00 to $61.00.
Hanger Orthopedic (HGR) had its “Buy” rating reiterated by Jefferies Group (NYSE:JEF).
Micros Systems (MCRS) had its “Buy” rating reiterated by Jefferies Group.
KB Home (KBH) was downgraded by Raymond James (NYSE:RJF) from a “Market Perform” rating to an “Underperform” rating.
Lennar Co. (LEN) was downgraded by Raymond James from an “Outperform” rating to a “Market Perform” rating.
Dresser-Rand (DRC) was upgraded by Pritchard from a “Neutral” rating to a “Buy” rating.
Showing posts with label Gilead Sciences. Show all posts
Showing posts with label Gilead Sciences. Show all posts
Tuesday, February 7, 2012
Monday, January 9, 2012
Nokia (NOK) (NPSP) (OMER) (AA) (DNDN) (GILD) Ratings Reiterated
Nokia Co. (NYSE: NOK), NPS Pharmaceuticals Incorporated (NASDAQ: NPSP), Omeros Corp. (NASDAQ: OMER), Alcoa Inc. (NYSE: AA), Dendreon Co. (NASDAQ: DNDN) and Gilead Sciences, Inc. (NASDAQ: GILD) had ratings on them reiterated by analysts.
Nokia Co. (NOK) had its “Hold” rating reiterated by Canaccord Genuity.
NPS Pharmaceuticals Incorporated (NPSP) had its “Buy” rating reiterated by Needham & Company.
Omeros Corp. (OMER) had its “Hold” rating reiterated by Needham & Company.
Alcoa Inc. (AA) had its “Hold” rating reiterated by Deutsche Bank (NYSE:DB).
Dendreon Co. (DNDN) had its “Neutral” rating reiterated by Robert W. Baird.
Gilead Sciences, Inc. (GILD) had its “Buy” rating reiterated by Needham & Company.
Nokia Co. (NOK) had its “Hold” rating reiterated by Canaccord Genuity.
NPS Pharmaceuticals Incorporated (NPSP) had its “Buy” rating reiterated by Needham & Company.
Omeros Corp. (OMER) had its “Hold” rating reiterated by Needham & Company.
Alcoa Inc. (AA) had its “Hold” rating reiterated by Deutsche Bank (NYSE:DB).
Dendreon Co. (DNDN) had its “Neutral” rating reiterated by Robert W. Baird.
Gilead Sciences, Inc. (GILD) had its “Buy” rating reiterated by Needham & Company.
Friday, January 6, 2012
Gilead (GILD) (MON) (AMCC) (APOL) (APU) (BMY) Ratings, Price Targets
Gilead Sciences, Inc. (NASDAQ: GILD), Monsanto Co. (NYSE: MON), Applied Micro Circuits Corp. (NASDAQ: AMCC), Apollo Group, Inc. (NASDAQ: APOL), Amerigas Partners Lp (NYSE: APU) and Bristol Myers Squibb Co. (NYSE: BMY) ratings and price targets.
Gilead Sciences, Inc. (GILD) had its “buy” rating reiterated by Needham & Company.
Monsanto Co. (MON) had its “conviction buy” rating reiterated by Goldman Sachs (NYSE:GS).
Applied Micro Circuits Corp. (AMCC) is now covered by Evercore Partners. They have an “overweight” rating on the company.
Apollo Group, Inc. (APOL) had its price target raised by JPMorgan Chase & Co. (NYSE:JPM) to $61.00.
Amerigas Partners Lp (APU) was downgraded by Bank of America (NYSE:BAC) to an “underperform” rating.
Bristol Myers Squibb Co. (BMY) was upgraded by CLSA from an “underperform” rating to an “outperform” rating.
Gilead Sciences, Inc. (GILD) had its “buy” rating reiterated by Needham & Company.
Monsanto Co. (MON) had its “conviction buy” rating reiterated by Goldman Sachs (NYSE:GS).
Applied Micro Circuits Corp. (AMCC) is now covered by Evercore Partners. They have an “overweight” rating on the company.
Apollo Group, Inc. (APOL) had its price target raised by JPMorgan Chase & Co. (NYSE:JPM) to $61.00.
Amerigas Partners Lp (APU) was downgraded by Bank of America (NYSE:BAC) to an “underperform” rating.
Bristol Myers Squibb Co. (BMY) was upgraded by CLSA from an “underperform” rating to an “outperform” rating.
Gilead Sciences (GILD) Ratings, Price Targets
Gilead Sciences (NASDAQ: GILD) ratings and price targets.
Needham & Company reiterated its "Buy" rating on Gilead Sciences (NASDAQ: GILD) today.
Citigroup (NYSE: C) reiterated a “Buy” rating on Gilead Sciences earlier in the week. They have a price target of $49.00 on the company.
JPMorgan Chase & Co. (NYSE: JPM) reiterated an "Overweight" rating on Gilead Sciences.
Oppenheimer (NYSE: OPY) boosted its price target on Gilead Sciences to $47.00. They have an "Outperform" rating on the company.
Gilead was trading at $42.83, gaining $0.31, or 0.74 percent, as of 11:59 AM EST.
Needham & Company reiterated its "Buy" rating on Gilead Sciences (NASDAQ: GILD) today.
Citigroup (NYSE: C) reiterated a “Buy” rating on Gilead Sciences earlier in the week. They have a price target of $49.00 on the company.
JPMorgan Chase & Co. (NYSE: JPM) reiterated an "Overweight" rating on Gilead Sciences.
Oppenheimer (NYSE: OPY) boosted its price target on Gilead Sciences to $47.00. They have an "Outperform" rating on the company.
Gilead was trading at $42.83, gaining $0.31, or 0.74 percent, as of 11:59 AM EST.
Wednesday, August 17, 2011
DISH (DISH) (URBN) (A) (LOW) (EL) (GILD) Price Targets Changed
DISH (NASDAQ: DISH), Urban Outfitters, Inc. (NASDAQ: URBN), Agilent Technologies Inc. (NYSE: A), Lowe’s (NYSE: LOW), Estee Lauder Companies Inc (NYSE: EL) and Gilead Sciences, Inc. (NASDAQ: GILD) price targets adjusted by analysts.
Urban Outfitters, Inc. (URBN) had its price target lowered by Barclays Capital from $37.00 to $35.00. They have an “Overweight” rating on the company.
Agilent Technologies Inc. (A) had its price target lowered by Deutsche Bank (NYSE:DB) from $61.00 to $48.00. They have a “Buy” rating on the company.
DISH (DISH) had its price target raised by Barclays Capital from $22.00 to $30.00. They have an “Equal Weight” rating on the company.
Lowe’s (LOW) had its price target lowered by Deutsche Bank from $30.00 to $26.00. They have a “Buy” rating on the company.
Estee Lauder Companies Inc. (EL) had its price target raised by Deutsche Bank from $90.00 to $95.00. They have a “Hold” rating on the company.
Gilead Sciences, Inc. (GILD) had its price target raised by Deutsche Bank from $45.00 to $53.00. They have a “Buy” rating on the company.
Urban Outfitters, Inc. (URBN) had its price target lowered by Barclays Capital from $37.00 to $35.00. They have an “Overweight” rating on the company.
Agilent Technologies Inc. (A) had its price target lowered by Deutsche Bank (NYSE:DB) from $61.00 to $48.00. They have a “Buy” rating on the company.
DISH (DISH) had its price target raised by Barclays Capital from $22.00 to $30.00. They have an “Equal Weight” rating on the company.
Lowe’s (LOW) had its price target lowered by Deutsche Bank from $30.00 to $26.00. They have a “Buy” rating on the company.
Estee Lauder Companies Inc. (EL) had its price target raised by Deutsche Bank from $90.00 to $95.00. They have a “Hold” rating on the company.
Gilead Sciences, Inc. (GILD) had its price target raised by Deutsche Bank from $45.00 to $53.00. They have a “Buy” rating on the company.
HiSoft (HSFT) (NOV) (FN) (GILD) (HRC) (ISRG) Price Targets Changed
HiSoft Technology International Limited (NASDAQ: HSFT), National-Oilwell Varco, Inc. (NYSE: NOV), Fabrinet (NYSE: FN), Gilead Sciences, Inc. (NASDAQ: GILD), Hill-Rom Holdings, Inc. (NYSE: HRC) and Intuitive Surgical, Inc. (NASDAQ: ISRG) price targets adjusted by analysts.
National-Oilwell Varco, Inc. (NOV) had its price target lowered by Morgan Keegan from $100.00 to $84.00. They have an “Outperform” rating on the company.
Fabrinet Ordinary (FN) had its price target lowered by Stifel Nicolaus from $30.00 to $25.00. They have a “Buy” rating on the company.
Gilead Sciences, Inc. (GILD) had its price target raised by Summer Street Research from $42.00 to $54.00. They have a “Buy” rating on the company.
Hill-Rom Holdings, Inc. (HRC) had its price target lowered by Morgan Keegan from $45.00 to $40.00. They have an “Outperform” rating on the company.
HiSoft Technology International Limited (HSFT) had its price target raised by Stifel Nicolaus from $20.00 to $22.00. They have a “Buy” rating on the company.
Intuitive Surgical, Inc. (ISRG) had its price target lowered by Morgan Keegan from $385.00 to $340.00. They have a “Market Perform” rating on the company.
National-Oilwell Varco, Inc. (NOV) had its price target lowered by Morgan Keegan from $100.00 to $84.00. They have an “Outperform” rating on the company.
Fabrinet Ordinary (FN) had its price target lowered by Stifel Nicolaus from $30.00 to $25.00. They have a “Buy” rating on the company.
Gilead Sciences, Inc. (GILD) had its price target raised by Summer Street Research from $42.00 to $54.00. They have a “Buy” rating on the company.
Hill-Rom Holdings, Inc. (HRC) had its price target lowered by Morgan Keegan from $45.00 to $40.00. They have an “Outperform” rating on the company.
HiSoft Technology International Limited (HSFT) had its price target raised by Stifel Nicolaus from $20.00 to $22.00. They have a “Buy” rating on the company.
Intuitive Surgical, Inc. (ISRG) had its price target lowered by Morgan Keegan from $385.00 to $340.00. They have a “Market Perform” rating on the company.
Wednesday, August 10, 2011
Molex (MOLX) (LPR) (AMAP) (EMR) (GILD) (APH) Get New Coverage
Molex Inc. (NASDAQ: MOLX), Lone Pine Resources (NYSE: LPR), AutoNavi Holdings Ltd (NASDAQ: AMAP), Emerson Electric Co. (NYSE: EMR), Gilead Sciences, Inc. (NASDAQ: GILD) and Amphenol Co. (NYSE: APH) get new coverage from analysts.
Macquarie initiated coverage on Molex Inc. (MOLX). They placed an “Outperform” rating on the company.
Scotia Capital initiated coverage on Lone Pine Resources (LPR). They placed a “Sector Perform” rating on the company.
Jefferies (NYSE:JEF) initiated coverage on AutoNavi Holdings Ltd (AMAP). They placed a “Buy” rating on the company.
Macquarie initiated coverage on Emerson Electric Co. (EMR). They placed an “Outperform” rating on the company.
Brean Murray initiated coverage on Gilead Sciences, Inc. (GILD). They placed a “Buy” rating and a price target of $52.00 on the company.
Macquarie initiated coverage on Amphenol Co. (APH). They placed a “Neutral” rating on the company.
Macquarie initiated coverage on Molex Inc. (MOLX). They placed an “Outperform” rating on the company.
Scotia Capital initiated coverage on Lone Pine Resources (LPR). They placed a “Sector Perform” rating on the company.
Jefferies (NYSE:JEF) initiated coverage on AutoNavi Holdings Ltd (AMAP). They placed a “Buy” rating on the company.
Macquarie initiated coverage on Emerson Electric Co. (EMR). They placed an “Outperform” rating on the company.
Brean Murray initiated coverage on Gilead Sciences, Inc. (GILD). They placed a “Buy” rating and a price target of $52.00 on the company.
Macquarie initiated coverage on Amphenol Co. (APH). They placed a “Neutral” rating on the company.
Monday, August 1, 2011
Potash (POT) (CNX) (CWEI) (VPRT) (STEC) (GILD) Downgraded
Potash Corp. (NYSE: POT), CONSOL Energy Inc. (NYSE: CNX), Clayton Williams Energy Inc. (NASDAQ: CWEI), VistaPrint (NASDAQ: VPRT), STEC Inc (NASDAQ: STEC) and Gilead Sciences, Inc. (NASDAQ: GILD) downgraded by analysts.
CONSOL Energy Inc. (CNX) was downgraded by Davenport from a “Buy” rating to a “Neutral” rating. They have a price target of $57.00 on the company, down from $59.00.
Clayton Williams Energy Inc. (CWEI) was downgraded by Global Hunter Securities from a “Buy” rating to a “Neutral” rating. They have a price target of $99.50 on the company, down from $101.75.
Potash Corp. (POT) was downgraded by Scotia Capital from an “Outperform” rating to a “Sector Perform” rating.
VistaPrint (VPRT) was downgraded by Piper Jaffray (NYSE:PJC) to an “Underweight” rating. They have a price target of $22.00 on the company.
STEC Inc. (STEC) was downgraded by Northland Securities from an “Outperform” rating to a “Market Perform” rating. They have a price target of $12.00 on the company, down from $23.00.
Gilead Sciences, Inc. (GILD) was downgraded by Citigroup (NYSE:C) from a “Hold” rating to a “Sell” rating. They have a price target of $27.00 on the company.
CONSOL Energy Inc. (CNX) was downgraded by Davenport from a “Buy” rating to a “Neutral” rating. They have a price target of $57.00 on the company, down from $59.00.
Clayton Williams Energy Inc. (CWEI) was downgraded by Global Hunter Securities from a “Buy” rating to a “Neutral” rating. They have a price target of $99.50 on the company, down from $101.75.
Potash Corp. (POT) was downgraded by Scotia Capital from an “Outperform” rating to a “Sector Perform” rating.
VistaPrint (VPRT) was downgraded by Piper Jaffray (NYSE:PJC) to an “Underweight” rating. They have a price target of $22.00 on the company.
STEC Inc. (STEC) was downgraded by Northland Securities from an “Outperform” rating to a “Market Perform” rating. They have a price target of $12.00 on the company, down from $23.00.
Gilead Sciences, Inc. (GILD) was downgraded by Citigroup (NYSE:C) from a “Hold” rating to a “Sell” rating. They have a price target of $27.00 on the company.
Thursday, July 14, 2011
Apple (AAPL) (AMGN) (GILD) (INFY) (NWSA) EPS Estimates Changed by Analysts
Apple, Inc (NASDAQ: AAPL), Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD), Infosys Technologies Ltd (NASDAQ: INFY) and News Corp. (NASDAQ: NWSA) had EPS estimates adjusted by analysts.
UBS AG (NYSE:UBS) boosted Apple, Inc (AAPL)‘s EPS estimate. They have a “Buy” rating and a price target of $510.00 on the company.
UBS AG raised Amgen, Inc. (AMGN) ‘s EPS estimate. They have a “neutral” rating and a price target of $58.00 on the company.
UBS AG cut its EPS estimate on Gilead Sciences, Inc. (GILD). They have a “Buy” rating and a price target of $47.00 on the company.
Oppenheimer increased its EPS estimate on Infosys Technologies Ltd (INFY). They have a “market perform” rating on the company.
Barclays Capital raised its EPS estimate on News Corp. (NWSA). They have an “Equal Weight” rating and a price target of $20.00 on the company. They had had a “Buy” rating on the company before the change.
News Corp. (NWSA) closed Wednesday at $15.93, gaining $0.58, or 3.78 percent. Infosys Technologies closed at $61.26, falling $0.18, or 0.29 percent. Gilead Sciences closed at $41.61, rising $0.06, or 0.14 percent. Amgen closed at $56.61, dropping $0.29, or 0.51 percent. Apple closed at $358.02, jumping $4.27, or 1.21 percent.
UBS AG (NYSE:UBS) boosted Apple, Inc (AAPL)‘s EPS estimate. They have a “Buy” rating and a price target of $510.00 on the company.
UBS AG raised Amgen, Inc. (AMGN) ‘s EPS estimate. They have a “neutral” rating and a price target of $58.00 on the company.
UBS AG cut its EPS estimate on Gilead Sciences, Inc. (GILD). They have a “Buy” rating and a price target of $47.00 on the company.
Oppenheimer increased its EPS estimate on Infosys Technologies Ltd (INFY). They have a “market perform” rating on the company.
Barclays Capital raised its EPS estimate on News Corp. (NWSA). They have an “Equal Weight” rating and a price target of $20.00 on the company. They had had a “Buy” rating on the company before the change.
News Corp. (NWSA) closed Wednesday at $15.93, gaining $0.58, or 3.78 percent. Infosys Technologies closed at $61.26, falling $0.18, or 0.29 percent. Gilead Sciences closed at $41.61, rising $0.06, or 0.14 percent. Amgen closed at $56.61, dropping $0.29, or 0.51 percent. Apple closed at $358.02, jumping $4.27, or 1.21 percent.
Friday, April 1, 2011
JPMorgan (JPM) Down on (NAV) (PFG) (VLY)
Even though JPMorgan (NYSE:JPM) downgraded the consumer discretionary sector from "Overweight" to "Neutral," that didn't stop stocks like Ford (NYSE:F) from jumping, as they surpassed General Motors (NYSE:GM) in sales for the month of March. Gambling businesses like Las Vegas Sands (NYSE:LVS) also went against the grain, as they have been rising on news gambling revenue in Macau soared.
The reasoning JPMorgan had behind the downgrading of the consumer discretionary sector, which they view as a short-term event, was that it has been overall "structurally weaker" for some time. They also see economic momentum starting to slow down while the sector continues to have high valuations.
As for other sectors, they pointed out some of their favorites and least favorite stocks, with their worst ones including Valley National (NYSE:VLY), Navistar (NYSE:NAV) and Principal Financial Group (NYSE:PFG).
Stocks that found favor with JPMorgan, among a number of them, include Amgen (NASDAQ:AMGN), Gilead (NASDAQ:GILD), Aetna (NYSE:AET), Cigna (NYSE:CI), Delta Airlines (NYSE:DAL), UAL (NYSE:UAL), Medco Health Solutions (NYSE:MHS) and Life Technologies Corp (NASDAQ:LIFE).
The reasoning JPMorgan had behind the downgrading of the consumer discretionary sector, which they view as a short-term event, was that it has been overall "structurally weaker" for some time. They also see economic momentum starting to slow down while the sector continues to have high valuations.
As for other sectors, they pointed out some of their favorites and least favorite stocks, with their worst ones including Valley National (NYSE:VLY), Navistar (NYSE:NAV) and Principal Financial Group (NYSE:PFG).
Stocks that found favor with JPMorgan, among a number of them, include Amgen (NASDAQ:AMGN), Gilead (NASDAQ:GILD), Aetna (NYSE:AET), Cigna (NYSE:CI), Delta Airlines (NYSE:DAL), UAL (NYSE:UAL), Medco Health Solutions (NYSE:MHS) and Life Technologies Corp (NASDAQ:LIFE).
Monday, March 7, 2011
JPMorgan (JPM) Recommends Newmont (NEM), (FCX), (MUSA), (STLD), Others
JPMorgan (NYSE:JPM), says Newmont Mining Corp. (NYSE:NEM), Metals USA Holdings Corp. (NYSE:MUSA), Freeport-McMoRan Copper & Gold Inc. (NYSE:FCX) and Steel Dynamics Inc. (NASDAQ:STLD) are solid picks if an investor believes oil prices will remain high.
Also noted were Thompson Creek Metals Co. (NYSE:TC), DHT Holdings Inc. (NYSE:DHT), Amgen Inc. (NASDAQ:AMGN), Jabil Circuit Inc. (NYSE:JBL) and Gilead Sciences Inc. (NASDAQ:GILD) as having a lot of potential in a high oil price environment.
Thomas Lee, chief U.S. equity strategist at JPMorgan said there’s “downside risk” to the 2011 S&P 500 earnings-per-share estimate of $97.50, though not to the 1,425 year-end forecast.
Lee said every $20-a-barrel rise in the price of oil has an impact of $2.22 in earnings per share for the Standard & Poor’s 500 Index.
Stocks JPMorgan sees as those to avoid in this economic environment are Affymetrix Inc. (NASDAQ:AFFX), Standard Pacific Corp. (NYSE:SPF), MDC Holdings Inc. (NYSE:MDC) and Beazer Homes USA Inc. (NYSE:BZH).
Also noted were Thompson Creek Metals Co. (NYSE:TC), DHT Holdings Inc. (NYSE:DHT), Amgen Inc. (NASDAQ:AMGN), Jabil Circuit Inc. (NYSE:JBL) and Gilead Sciences Inc. (NASDAQ:GILD) as having a lot of potential in a high oil price environment.
Thomas Lee, chief U.S. equity strategist at JPMorgan said there’s “downside risk” to the 2011 S&P 500 earnings-per-share estimate of $97.50, though not to the 1,425 year-end forecast.
Lee said every $20-a-barrel rise in the price of oil has an impact of $2.22 in earnings per share for the Standard & Poor’s 500 Index.
Stocks JPMorgan sees as those to avoid in this economic environment are Affymetrix Inc. (NASDAQ:AFFX), Standard Pacific Corp. (NYSE:SPF), MDC Holdings Inc. (NYSE:MDC) and Beazer Homes USA Inc. (NYSE:BZH).
Thursday, January 27, 2011
Gilead (Nasdaq:GILD) Ends 2010 with a Revenue Drop
With the hyped-up concern over swine flu not materializing last year, Gilead (Nasdaq:GILD) finished the last quarter of the year with negative revenue, the first time since 1999.
A big part of income for Gilead is royalties they receive from Roche from their part in developing Tamiflu. In a down year it significantly reflects on revenue, and ultimately, earnings.
Royalty income is especially important because it goes direct to earnings because of the lack of cost inputs in royalties.
Product sales for the quarter were up 7 percent over the same period last year, led by HIV treatment Atripla.
Also pushing earnings down was increased spend in the R&D budget. That's not a bad thing as long as a strong pipeline is established.
Gilead was trading at $39.08, down $0.58, or 1.48 percent, as of 12:37 PM EST.
A big part of income for Gilead is royalties they receive from Roche from their part in developing Tamiflu. In a down year it significantly reflects on revenue, and ultimately, earnings.
Royalty income is especially important because it goes direct to earnings because of the lack of cost inputs in royalties.
Product sales for the quarter were up 7 percent over the same period last year, led by HIV treatment Atripla.
Also pushing earnings down was increased spend in the R&D budget. That's not a bad thing as long as a strong pipeline is established.
Gilead was trading at $39.08, down $0.58, or 1.48 percent, as of 12:37 PM EST.
Wednesday, January 26, 2011
Gilead Sciences' (NASDAQ:GILD) Truvada-TMC278 Delayed Several Months
Gilead Sciences (NASDAQ:GILD) received a "Refuse to File" letter from the FDA concerning fixed-dose combination pill Truvada-TMC278. That should result in a delay of several months.
Jefferies noted, "the FDA requested additional information in the CMC section on new analytical methods to characterize identified degradants of the Emtriva component of Truvada."
Gilead said they'll get the information in the hands of the FDA sometime in the first quarter of 2011.
Jefferies raised their full year 2011 EPS estimate on Gilead from $4.07 to $4.13.
Jefferies Maintains Hold Rating on Gilead Sciences (GILD), which was trading at $39.45, gaining $1.29, or 3.38 percent, as of 2:36 PM EST. Jefferies raised their price target on Gilead from $41 to $42.
Jefferies noted, "the FDA requested additional information in the CMC section on new analytical methods to characterize identified degradants of the Emtriva component of Truvada."
Gilead said they'll get the information in the hands of the FDA sometime in the first quarter of 2011.
Jefferies raised their full year 2011 EPS estimate on Gilead from $4.07 to $4.13.
Jefferies Maintains Hold Rating on Gilead Sciences (GILD), which was trading at $39.45, gaining $1.29, or 3.38 percent, as of 2:36 PM EST. Jefferies raised their price target on Gilead from $41 to $42.
Thursday, January 6, 2011
Gilead Sciences (NASDAQ:GILD) Undervalued on HCV Pipeline Says Needham
Gilead Sciences (NASDAQ:GILD) is considered to be undervalued according to Needham & Company, which says their growing presence in the HCV space and strong balance sheet isn't appreciated.
Needham says, "Concerns around long-term growth have been an issue for the stock. We believe pipeline progression with both HIV and HCV programs in 2011 may restore investor enthusiasm. Gilead is now more relevant in the HCV space and given its balance sheet, deep clinical HCV pipeline, and expertise with combination antiviral therapy, has the potential to surpass competitors in the space. The stock is undervalued in our view and we reiterate our rating."
Needham & Company reiterates a "Buy" on Gilead Sciences, which was trading at $37.66, gaining $0.13, or 0.35 percent, as of 12:02 PM EST. Needham has a price target of $48 on Gilead.
Needham says, "Concerns around long-term growth have been an issue for the stock. We believe pipeline progression with both HIV and HCV programs in 2011 may restore investor enthusiasm. Gilead is now more relevant in the HCV space and given its balance sheet, deep clinical HCV pipeline, and expertise with combination antiviral therapy, has the potential to surpass competitors in the space. The stock is undervalued in our view and we reiterate our rating."
Needham & Company reiterates a "Buy" on Gilead Sciences, which was trading at $37.66, gaining $0.13, or 0.35 percent, as of 12:02 PM EST. Needham has a price target of $48 on Gilead.
Thursday, December 23, 2010
Gilead Sciences (NASDAQ:GILD) Terminates ARTEMIS-IPF Phase III Study
Citing lack of efficacy, Gilead Sciences (NASDAQ:GILD) announced they have terminated their ARTEMIS-IPF Phase III study.
Wedbush said, "Last night, Gilead announced termination of the ARTEMIS-IPF Phase III study due to lack of efficacy...We believe the termination of ambrisentan in IPF will be only slightly negative on GILD stock, as the Street has not modeled any sales from this indication. And this termination is positive for ITMN, whose Esbriet received a Positive Opinion from the CHMP last week and�is poised to be approved for mild-to-moderate IPF in the EU during Q1:11...An acquisition of Intermune (Nasdaq: ITMN) may be a strategic fit for GILD, especially given the failure of ambrisentan in IPF."
Wedbush maintains an "Underperform" rating on Gilead Sciences, which was trading at $36.01, down $0.33, or 0.91 percents, as of 12:28 PM EST. Wedbush has a price target on them of $40.
Wedbush said, "Last night, Gilead announced termination of the ARTEMIS-IPF Phase III study due to lack of efficacy...We believe the termination of ambrisentan in IPF will be only slightly negative on GILD stock, as the Street has not modeled any sales from this indication. And this termination is positive for ITMN, whose Esbriet received a Positive Opinion from the CHMP last week and�is poised to be approved for mild-to-moderate IPF in the EU during Q1:11...An acquisition of Intermune (Nasdaq: ITMN) may be a strategic fit for GILD, especially given the failure of ambrisentan in IPF."
Wedbush maintains an "Underperform" rating on Gilead Sciences, which was trading at $36.01, down $0.33, or 0.91 percents, as of 12:28 PM EST. Wedbush has a price target on them of $40.
Subscribe to:
Posts (Atom)